Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Phase 2 Unknown 80 enrolled Zhejiang University Merck Sharp & Dohme LLC · collab

RandomizedParallel-groupOpen-labelSupportive care

Summary

Aprepitant is an oral neurokinin-1(NK-1) antagonist which is used for the prevention of chemotherapy-induced nausea and vomiting (CINV). This phase II clinical trial was designed to evaluate the efficacy of aprepitant in the prevention of CINV with lung cancer patients receiving 3-day cisplatin-based chemotherapy.

Timeline

Start: 2015-12
Primary completion: 2016-05
Completion: 2016-05

Publications

Results Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy. Intern Med J. 2013 Jan;43(1):73-6. doi: 10.1111/j.1445-5994.2011.02637.x.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aprepitant	Other / unclassified	80 mg	Oral
Background	Dexamethasone	Small molecule	3.75 mg	Intravenous
Background	Dexamethasone	Small molecule	7.5 mg	Intravenous
Background	Palonosetron	Other / unclassified	0.25 mg	Intravenous

Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy

Summary

Timeline

Publications

Drugs

Indications